KDIGO(KIDNEY DISEASE IMPROVING GLOBAL OUTCOMES) 2024

HOLISTIC APPROACH FOR IMPROVING OUTCOMES IN PATIENTS WITH DIABETES AND CKD



CHALLENGES IN DIABETES MANAGEMENT AND CKD



CKD in diabetes is underdiagnosed and therefore may not be appropriately addressed¹

At least 67% of patients with diabetes and CKD by laboratory criteria failed to have appropriate CKD or DKD documentation in the electronic medical record.



Patients with diabetes and CKD

- Are in high-risk socioeconomic groups²
- Often have an insulin treatment prevalence>50%,^{2,3}
- Have frequent hypo- and hyper- glycemia that may not be captured by traditional methods (finger stick blood glucose and A1c)^{4,5}



Traditional monitoring of glucose control by A1C may be confounded by⁵

- Increased red blood cell turnover
- Acidosis
- Iron supplements

TREATMENT GUIDELINES FOR MANAGEMENT OF CKD⁶

Lifestyle



Healthy diet



Physical activity



Smoking cessation




Weight management

Regular risk factor assessment (every 3-6 months)

First-line drug therapy for most patients

Targeted therapies for complications







Aim for SBP <120mm Hg RAS inhibitor* at maximum tolerated dose (if HTN)







Statin-based therapy moderate- or high-intensity statin



ASCVD risk, lipids

Manage hyperglycemia as per the KDIGO Diabetes Guideline, including use of GLP-1 RA where indicated



Use ns-MRA in people with diabetes and an indication for use





Dihydropyridine CCB and/or diuretic if needed to achieve individualized BP target



Antiplatelet agent for clinical ASCVD

CKD-MBD, acidosis, and potassium abnormalities, where indicated

Manage anemia,

Steroidal MRA if needed for resistant hypertension if eGFR ≥45



Use the same principles to diagnose and manage ASCVD and atrial fibrillation as in people without CKD


Ezetimibe, PCSK9i

indicated based on

ASCVD risk and lipids









1. Clinical Kidney Journal, 2022, vol. 15, no. 10, 1865-1871; 2. Clemens K, et al KIDNEY360 2: 653-665, 2021; 3. Rhee et al. BMC Nephrology (2015) 16:204; 4. Qayyum, et al Blood Purif 2016;41:18-24; 5. Galindo, R et al, Endocrine Reviews, October 2020, 41(5):756-774; 6. Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.